Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefprozil 250 mg/5 mL Oral Suspension Versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects

NCT00778739 is registered in ClinicalTrials.gov with Ranbaxy Laboratories Limited as lead sponsor.

NCT NCT00778739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00778739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefprozil 250 mg/5 mL Oral Suspension Versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects
Lead sponsor
Ranbaxy Laboratories Limited
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2005
Completion date
July 31, 2005
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy